Pharmalot -- The cost-per-QALY (Quality-Adjusted Life years) pricing model is a trick used by drugmakers to raise prices, and as a pricing instrument it is “going completely the wrong way,” because the benefits to patients cannot be quantified, according to a German health insurance expert, PharmaTimes writes.
